GlassScriptPhysician profile
Kimberly J Ramirez
NPI 1831535103
$1,521.66
in general payments reported to CMS, 2019-2025
18 companies · $295 in 2025
The $295 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.93 · 2020: $156 · 2021: $60.77 · 2022: $379 · 2023: $276 · 2024: $315 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $373.90 | 2022-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Pfizer INC. | $218.83 | 2020-2024 | |
| Sanofi Pasteur INC. | $176.90 | 2022-2025 | |
| Cranial Technologies, INC | $144.52 | 2019-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $117.93 | 2020-2023 | Vpriv |
| Glaxosmithkline, LLC. | $88.35 | 2020-2024 | Bexsero |
| Sanofi-Aventis U.S. LLC | $83.09 | 2023-2025 | |
| Sobi, INC | $64.08 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $49.39 | 2023-2024 | Flumist Quadrivalent |
| Ars Pharmaceuticals Operations, INC. | $42.38 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $31.62 | 2024 | Dupixent |
| Arbor Pharmaceuticals, INC. | $26.76 | 2019-2020 | |
| Krystal Biotech INC | $25.00 | 2024 | Vyjuvek |
| Kaleo, INC. | $21.40 | 2022 | |
| Seqirus USA INC | $19.97 | 2023 | Flucelvax Quadrivalent |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $19.00 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.78 | 2022 | |
| Organon LLC | $3.76 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.